SCHEMBL205578

SCHEMBL205578

Brc1ccc2c(c1)Nc1ccc(Br)cc1S2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 6/20 0.58
NOX1 Q9Y5S8 13/20 0.48
GAA P10253 4/20 0.48
MAPT P10636 4/20 0.48
MAPK1 P28482 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
ALOX15 P16050 2/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CYP3A4 P08684 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
ALOX12 P18054 1/20 0.45
MAOA P21397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30065446 1.00 SNCA (0.58) SNCANOX1GAAMAPTMAPK1
SCHEMBL28407357 0.92 SNCA (0.47) SNCANOX1GAAMAPTMAPK1
SCHEMBL2582828 0.92 SNCA (0.66) SNCANOX1GAAMAPTMAPK1
SCHEMBL29637682 0.92 SNCA (0.66) SNCANOX1GAAMAPTMAPK1
Bromide SCHEMBL30448580 0.90 SNCA (0.64) SNCANOX1GAAMAPTMAPK1
Bromide SCHEMBL20495634 0.90 SNCA (0.64) SNCANOX1GAAMAPTMAPK1
SCHEMBL28635096 0.88 NOX1 (0.65) SNCANOX1GAAMAPTMAPK1
SCHEMBL4706809 0.86 SNCA (0.45) SNCANOX1GAAMAPTMAPK1
SCHEMBL30769565 0.86 NOX1 (0.65) SNCANOX1GAAMAPTMAPK1
SCHEMBL239782 0.86 NOX1 (0.65) SNCANOX1GAAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115490854-B Polyimide with low dielectric, high heat resistance and low water absorption and high performance, and preparation method and application thereof 江西有泽新材料科技有限公司 2024-01-30 CN claimed
CN-115490854-A Low-dielectric, high-heat-resistant and low-water-absorption high-performance polyimide, and preparation method and application thereof 江西有泽新材料科技有限公司 2022-12-20 CN claimed
CN-115490854-B Polyimide with low dielectric, high heat resistance and low water absorption and high performance, and preparation method and application thereof 江西有泽新材料科技有限公司 2024-01-30 CN disclosed
CN-111087364-B Antibacterial diamine prepared from medical intermediate and preparation method thereof 广东高义包装科技股份有限公司 2023-03-31 CN disclosed
CN-115490854-A Low-dielectric, high-heat-resistant and low-water-absorption high-performance polyimide, and preparation method and application thereof 江西有泽新材料科技有限公司 2022-12-20 CN disclosed
CN-112979582-A Preparation method of diamine containing phenothiazine structure and synthetic polyimide 湖南工业大学 2021-06-18 CN disclosed
CN-106588890-B Antiviral compounds 吉利德制药有限责任公司 2020-11-27 CN disclosed
CN-111763182-A Diamine containing phenothiazine and amide structures and polyimide thereof 湖南工业大学 2020-10-13 CN disclosed
CN-111087364-A Antibacterial diamine prepared from medical intermediate and preparation method thereof 湖南工业大学 2020-05-01 CN disclosed
EP-3626716-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-03-25 EP disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 US disclosed
US-8273341-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-09-25 US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 SNCA 2309/4885NOX1 3704/4885GAA 151/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 SNCA 2309/4885NOX1 3704/4885GAA 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.